Browse by category

The initial results of a study assessing the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence, has reported that after 12 months, the average total body weight loss was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. “These results provide additional data that a combination approach with the Allurion Smart Capsule and GLP-1 medications has several advantages,” said

A presentation of a study entitled “The swallowable gastric balloon program with AI powered health coach leads to metabolically healthy...

This World Health Day, it is time to confront obesity. Despite advances in obesity treatments, the obesity epidemic continues to...

Allurion Technologies has announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimise...

Allurion Technologies has announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an...

Allurion Technologies has announced that the Somerset NHS Foundation Trust is the first NHS trust in the UK - and the first non-private...

Allurion has entered a pilot collaboration agreement with Medtronic, to expand access to Allurion’s AI-powered weight loss programme...

Allurion Technologies and Compute Health Acquisition have entered into a definitive business combination agreement that will result in...